Introduction
During the multi-step process of cancerogenesis, growth constraints are classically impaired by loss and/or mutation of both alleles of critical tumour suppressor genes (Hanahan and Weinberg, 2000) . Tumour suppressors can also be eectively inactivated by silencing through hypermethylation of CpG islands within their promoter regions (Jones and Laird, 1999; Momparler and Bovenzi, 2000) . In addition, other mechanisms of tumour suppressor gene inactivation are likely to exist as exempli®ed for the BRCA1 gene. In sporadic ovarian carcinomas, the prevalence of mutations in the coding region of the BRCA1 gene was low and hypermethylation of the BRCA1 regulatory region was shown only in a small fraction of samples (Baldwin et al., 2000) . Nevertheless, the BRCA1 protein was not detectable in approximately 90% of these tumours (Russell et al., 2000) . Thus, in sporadic ovarian carcinomas BRCA1 is inactivated by another, unknown mechanism (Catteau et al., 1999) .
The concept of the reversible expression block as a general mechanism of tumour suppressor gene inactivation was established several years ago (Sager, 1997) . These genes were designated class II tumour suppressor genes and contrasted from class I genes which have sustained mutations in cancer. Until now, the regulatory mechanisms responsible for the downregulation of class II tumour suppressor genes which are distinct from methylation have not yet been elucidated in much detail. Impairment of class I tumour suppressors such as p53 can cause a diminished class II gene expression. For example, wild-type p53 stimulates the expression of the angiogenesis inhibitor thrombospondin (Dameron et al., 1994) , the signalling regulator caveolin-1 (CAV1; Bist et al., 2000) and the serine protease inhibitor maspin (Zou et al, 2000) . Mutational inactivation or loss of p53 results in the loss of transcriptional activator function and tumour suppressor gene down-regulation. Overall, the mechanisms of transcriptional down-regulation may be even more complex. Down-regulation of the maspin gene in human breast cancer was also reported to occur as a result of reduced transactivation normally mediated by AP-1 and Ets transcription factors (Zhang et al, 1997) . Signal transduction pathways initiated by oncogenic RAS genes repress transcription of a large set of negative growth regulators. This indicates a functional link between oncogene activity and growth suppressor inactivation (SchaÈ fer, 1994; Zuber et al, 2000) . These results support the notion that silencing tumour suppressor expression may be a frequent event in cancer progression, while mutations in cellular oncogenes like RAS or class I tumour suppressor genes such as p53 are mainly responsible for tumour initiation.
To further elucidate the frequency of suppressor gene down-regulation and the mechanism of nonmutational inactivation, we have analysed the expression of the H-REV107-1 gene which was isolated as a RAS-responsive gene by cDNA subtraction (Hajnal et al., 1994) . H-REV107-1 mRNA is almost ubiquitously present in normal tissues, but not expressed in most human tumour cell lines (Husmann et al., 1998) . Forced expression of the rat H-rev107-1 gene resulted in growth inhibition of RAS-transformed cells in vitro and in vivo (Sers et al., 1997 ). Here we show that H-REV107-1 expression is diminished in approximately 50% of ovarian carcinomas. H-REV107-1 expression is reversibly down-regulated via the MAP/ERK pathway in a subset of tumour cells. In addition, we demonstrate that the expression of H-REV107-1 is positively controlled by the tumour suppressor interferon regulatory factor-1 (IRF-1). In tumour cells, a decreased IRF-1 expression and reduced sensitivity of the H-REV107-1 gene towards IRF-1-mediated activation is likely to result in loss of H-REV107-1 expression.
Results

Down-regulation of H-REV107-1 in human ovarian carcinomas
The H-REV107-1 gene is ubiquitously expressed in most normal tissues, however, expression is lost in human tumour cell lines and tumour samples (Husmann et al., 1998) . To view the distribution of dierential H-REV107-1 expression in a larger set of primary and metastatic tumours, we hybridized a Cancer Pro®ling cDNA Array (Clontech TM ) with an H-REV107-1-speci®c probe. This array represents 241 RNA-derived cDNA pairs of matched normal and tumour tissues of individual patients normalized for the expression of three dierent housekeeping genes Zhumabayeva and Adhikari, 2001) . The H-REV107-1 probe revealed expression of the gene in all normal tissues with the most abundant expression in breast and kidney (data not shown). Lower levels of H-REV107-1 transcripts are present in stomach, uterus, lung, ovary, thyroid and prostate and weak expression is detectable in colon and rectum. In 28 out of 52 primary or metastatic breast tumours, in 10 out of 21 lung tumours and in 7 out of 14 ovarian tumours, H-REV107-1 expression levels were diminished twofold or more ( Figure 1a and data not shown).
We extended the analysis of primary tumours and performed semi-quantitative RT ± PCR in human ovarian tissue specimens. A strong H-REV107-1-speci®c PCR-product was detected in two mRNA samples from normal ovary, but not in the corresponding tumour samples (N1/T1 and N2/T2, Figure 1b) . A weaker but similar expression was visible in the third matched pair consisting of normal tissue and borderline tumour from the same patient (N3/T3). Immunohistochemical analysis using an H-REV107-1-speci®c antiserum revealed a strong expression of the H-REV107-1 protein in normal ovarian epithelium. A heterogeneous loss of the protein in up to 90% of tumour cells was observed in grade 2 and grade 3 ovarian carcinomas (Figure 1c ± f and Table 1 ). In a few samples, a strong H-REV107-1-speci®c signal was detected within the nuclei of the tumour cells ( Figure  1f ). These data con®rmed our observations obtained from the Cancer Pro®ling Array and demonstrate down-regulation of H-REV107-1 in a signi®cant fraction of high grade ovarian carcinomas.
H-REV107-1 expression is suppressed by two different mechanisms in ovarian cancer cells
To investigate the mechanism responsible for loss of H-REV107-1 in ovarian carcinomas, we analysed expression of the gene in normal and transformed rat and human ovarian epithelial cells in vitro. Hrev107-1 is strongly expressed in immortalized rat ovarian surface epithelial cells (ROSE 199) (Adams and Auersperg, 1985) , but undetectable in a KRAS transformed derivative, ROSE A2/5 cells (Figure 2a) . Analysis of human cells revealed a strong H-REV107-1 expression in the immortal HOSE cells but only weak expression is detected in the carcinoma cell lines OVCAR-3 and no expression was detected in A27/ 80 cells (Figure 2b ). In contrast, SKOV-3 ovarian carcinoma cells express high levels of H-REV107-1. Upon pharmacological inhibition of the MAP/ERK pathway using the MEK1 inhibitor PD98059, Hrev107-1 expression was restored in the KRAStransformed ROSE A2/5 cells. Inhibition of the PI-3 kinase pathway by LY294002 had no eect onto Hrev107-1 expression in ROSE A2/5 cells and both inhibitors did not modulate H-rev107-1 expression in the immortal cell line ROSE 199 (Figure 2a ). This demonstrated that the H-rev107 gene can be reversibly down-regulated in epithelial cells upon RAS-dependent activation of the MAP/ERK pathway. Stimulation of this pathway induced by mutational RAS activation or by other alterations not involving genetic damage to RAS has been described in human ovarian tumours and tumorigenic cell lines (Patton et al., 1998) , in breast tumours (von Lintig et al, 2000) and pancreatic tumours (Yip-Schneider et al, 1999) . To ®nd out whether down-regulation of the H-REV107-1 gene in human ovarian carcinomas also depends on signal transduction pathways downstream of RAS, we investigated mRNA levels in seven human ovarian carcinoma cell lines following inhibition of the MAP/ ERK or the PI-3 kinase pathway. H-REV107-1 is partially suppressed via an activated MAP/ERK pathway only in the PA1 ovarian teratocarcinoma cell line which harbours an activated NRAS oncogene (Figure 2c ) (Tainsky et al., 1984) , but not in any of the other epithelial carcinoma cell lines. These results show that both the rat and the human H-REV107-1 genes can be a target of activated RAS oncogenes, irrespective of the RAS isoform. In addition to the down-regulation by RAS-dependent signalling, other mechanisms must exist in human cancer cell lines.
Down-regulation of H-REV107-1 in human ovarian carcinoma cells is reverted upon incubation with IFNg
One year after the isolation of the rat gene (Hajnal et al., 1994) , Kuchinke et al. , recovered H-rev107-1-related sequences by dierential display in cDNA derived from interferon-g-treated astrocytoma cells indicating that the gene is an IFNg target (Kuchinke et al., 1995) . Interferons exert inhibitory eects on tumour cell growth and recently it was described that IFNg improved survival of ovarian carcinoma patients (Windbichler et al, 2000) . Therefore we tested the eects of IFNg on H-REV107-1 expression in human Figure 1 Down-regulation of H-REV107-1 in human ovarian carcinomas. (a) A Cancer Pro®ling Array representing cDNA pools from matched tumour and normal tissues was hybridized using a H-REV107-1 speci®c probe. cDNA representing normal ovarian tissue is spotted in the upper panel (N), cDNA prepared from the corresponding ovarian carcinomas in the lower panel (T). Spots were evaluated by phospho-image analysis and the ratio tumour/normal of each pair is shown below. Background was subtracted from each spot. $ indicates a cDNA derived from a metastasis of the preceding tumour pair. The histopathological classi®cation of the tumour probes used for cDNA preparation can be viewed at http://www.clontech.com/techinfo/manuals/index.shtml. (b) RT ± PCR analysis of H-REV107-1 in RNA prepared from normal human ovarian tissue samples and ovarian carcinomas. Fifty ng of total RNA from each tissue sample were reverse transcribed and ampli®ed using the H-REV107-1 primers 107-A and 107-G, or G3PDH-speci®c primers as described in Materials and methods. Five ml of each 25 ml reaction were separated on a 1% agarose gel. 7 and + indicate negative and positive controls, respectively. N: normal tissue, T: tumour tissues. Samples are matched pairs derived from the same patients. T1: dysgerminoma, T2: adeno®broma, T3: tumour of borderline malignancy. Each sample was tested at least twice. (c ± f) Immunohistochemical analysis of H-REV107-1 expression in normal ovary and ovarian carcinomas. A strong H-REV107-1 speci®c signal is detected in the epithelial lining of the normal ovary and in the underlying cortical stroma (c). The atypical epithelium of a serous adenoma shows a similar strong expression (d) which is completely lost in a grade 2 serous ovarian carcinoma (e). In some rare cases, a strong nuclear staining was detected in a small fraction of carcinoma cells in (f, grade 3, serous carcinoma) ovarian carcinoma cells. Incubation of the cell lines A27/80 and OVCAR-3 with either 100 U/ml or 1000 U/ ml recombinant human IFNg resulted in an upregulation of H-REV107-1 (Figure 3a) . A time course experiment revealed maximal H-REV107-1 induction after 12 h in OVCAR-3 incubated with 100 U/ml IFNg and after 24 h in A27/80 cells incubated with 1000 U/ml IFNg. Surprisingly, we detected much higher H-REV107-1 induction in OVCAR-3 cells using IFNg at 100 U/ml as compared to 1000 U/ml.
The interferon-regulatory factors (IRFs) are transcription factors which are up-regulated in response to IFNg and other interferons. IRFs mediate several IFNdependent eects (Tanaka and Taniguchi, 2000) . IRF-1 itself has been implicated in oncogenesis and was suggested to act as a tumour suppressor in human carcinomas. Investigation of IRF-1 expression in IFNgtreated A27/80 and OVCAR-3 carcinoma cell lines showed that concomitant with increased H-REV107-1 mRNA levels, IRF-1 expression was elevated ( Figure 3a) . To test whether H-REV107-1 is a direct target of IRF-1, we ®rst used a NIH3T3 derivative engineered to conditionally express IRF-1 as a fusion protein with the human estrogen receptor (Kirchho et al., 1995) . Upon induction of IRF-1 by estradiol, a strong H-rev107-1 expression was detectable after 48 h both in the presence and in the absence of cycloheximide (Figure 3b ). Incubation of parental NIH3T3 cells with estradiol could not induce H-rev107-1 expression (data not shown). These observations demonstrate that H-rev107-1 is a direct target of the IRF-1 tumour suppressor protein. The low expression levels and the inducibility of the IRF-1 gene in A27/80 and OVCAR-3 ovarian carcinoma cell lines in response to IFNg prompted us to investigate whether IRF-1 levels dier between immortal and tumorigenic cell lines. As shown in Figure 3c , HOSE cells express considerably higher levels of IRF-1 mRNA in the absence of IFNg as compared to the four tumour cell lines.
For a more detailed analysis of the relationship between H-REV107-1 and IRF-1 expression, we transfected ovarian carcinoma cell lines with an IRF-1 expression construct. To evaluate transfection eciencies, A27/80, OVCAR-3, PA-1 and ES-2 ovarian cancer cell lines were tested using an enhanced green¯uorescent Thirty eight samples were stained and a semiquantitative analysis of the intensities was performed. Staining intensity was graded as 1 (weakly positive), 2 (moderately positive) and 3 (strongly positive). Per cent of tumor cells stained indicates the range of positive cells counted in the indivdual tumors of each group H-REV107-1 is a target of interferon-regulatory factor-1 C Sers et al protein-expression vector. Only the teratocarcinoma cell line PA-1 and the epithelial ovarian carcinoma cell line ES-2 could be reproducibly transfected to rates of approximately 30% (data not shown). Northern blot analysis revealed that up-regulation of H-REV107-1 after transient transfection of IRF-1 was detectable in ES-2 and PA-1 (Figure 4) . A weak elevation of the H-REV107-1 mRNA level was observed in OVCAR-3 cells and no eect could be detected in A27/80 cells. The latter observations are most likely the result of the very low transfection eciencies. These experiments clearly show that H-REV107-1 expression can be stimulated in ES-2 human ovarian carcinoma cells by IRF-1. Furthermore, up-regulation of H-REV107-1 in these experiments was detected in the PA-1 teratocarcinoma cells. In these cells we have also observed regulation of H-REV107-1 via the Figure 3 H-REV107-1 expression is restored in A27/80 and OVCAR-3 cells upon IFNg-treatment. (a) Cells were incubated with 100 U/ml or 1000 U/ml IFNg for the time indicated prior to RNA preparation. Northern blots were ®rst hybridized to the H-REV107-1 speci®c probe and afterwards to an IRF-1 speci®c probe. To control for equal loading, blots were stripped and hybridized to a 28S-speci®c probe. (b) H-rev107-1 is a direct target of the interferon regulatory factor-1 (IRF-1). Upper panel: Northern blot analysis of KA1-10/96-1A cells incubated either in standard medium with low estrogen (7) or in the presence of 1 mM b estradiol alone (E) or together with 20 mg/ml cycloheximide (E+C) for 48 h prior to RNA preparation. Lower panel: Western blot analysis of H-rev107-1 expression in KA1-10/96-1A cells (7) and after induction with estradiol (E). (c) Down-regulation of H-REV107-1 expression in A27/80 and OVCAR-3 ovarian carcinoma cells is correlated with reduced levels of IRF-1. Expression of H-REV107-1 and IRF-1 was analysed in the immortalized ovarian epithelial cells HOSE, in the epithelial ovarian carcinoma cell lines SKOV-3, OVCAR-3 and A27/80 and in the teratocarcinoma cell line PA1. To detect the weak IRF-1 signal present in A27/80 and PA1 cells, the Northern blot was exposed for 3 days MAP/ERK pathway (compare Figure 2c) . Whether activation of MAP/ERK signalling and loss of IRF-1 in these cells contribute equally to the regulation of H-REV107-1 gene needs to be investigated.
H-REV107-1 suppresses colony formation of ovarian carcinoma cells and is involved in IFNg-dependent cell death
The restoration of H-REV107-1 expression upon IFNg treatment in A27/80 and OVCAR-3 cells suggested a potential involvement of the gene in IFNg-mediated growth suppression. To test this, we introduced an H-REV107-1 expression plasmid into A27/80 and OV-CAR-3 cells. H-REV107-1 reduced colony formation in A27/80 cells by approximately 50%. In contrast, no signi®cant eect of H-REV107-1 expression was detected in OVCAR-3 cells ( Figure 5 ). When we investigated the eects of IFNg itself onto growth of both cell lines, the A27/80 cell line showed considerable sensitivity towards IFNg and growth was inhibited up to 50%. OVCAR-3 cells were resistant and could not be suppressed after 72 and 96 h with up to 1000 U/ml of IFNg (data not shown). These results demonstrate that in IFNg-sensitive cell lines such as A27/80, H-REV107-1 is likely to contribute to the cytokinemediated growth inhibition. We wished to determine the mechanism of H-REV107-1 mediated growth suppression in ovarian carcinoma cells. Therefore we investigated the phenotype of A27/80 and OVCAR-3 cells after transient transfection of H-REV107-1 and after induction with IFNg at a single cell level. In both cell lines, we observed a nuclear morphology indicative of apoptosis only in cells which expressed high levels of H-REV107-1 protein 48 h after transfection (Figure 6a,b) . More importantly, expression of the H-REV107-1 protein was also detected 48 h after incubation of OVCAR-3 cells with 100 U/ml IFNg and similarly to the transfected cells, apoptotic nuclei were detected only in cells expressing high levels of H-REV107-1 ( Figure  6c) . However, only a small fraction of cells showed upregulation of H-REV107-1 to detectable levels in OVCAR-3 cells (55%). Therefore, the speci®c H-REV107-1 signal detected by Western blot analysis was very low (Figure 6d ). In A27/80 cells, endogenous H-REV107-1 levels present in the cells after incubation with IFNg were even lower and hardly detectable by immuno¯uorescence or Western blot analysis (data not shown).
These experiments suggest that both forced and IFNg-induced high levels of H-REV107-1 protein expression in human ovarian carcinoma cells result in cell death. In most carcinoma cells, however, high expression levels of H-REV107-1 which can be detected in normal epithelial cells in situ, are prevented.
Discussion
Our study provides evidence that expression of the class II tumour suppressor gene H-REV107-1 is strongly reduced in 50% of human ovarian carcinomas. We identi®ed two dierent modes of H-REV107-1 regulation in established ovarian cell lines: The gene is completely down-regulated in KRAS-transformed A2/5 rat ovarian epithelial cells and partially repressed in human PA1 ovarian teratocarcinoma cells which express a mutated NRAS gene (Tainsky et al, 1984) . Down-regulation of the H-REV107-1 gene is dependent on activated MAP/ERK signalling, since expression is restored (A2/5) or elevated (PA1) in the presence of the MEK inhibitor PD98059. In contrast, H-REV107-1 expression is not subject to regulation by the MAP/ ERK signal transduction pathway in OVCAR-3 and A27/80 ovarian carcinoma cells, but is stimulated in response to IFNg. Treatment of both cell lines with Blots were stripped and hybridized with an IRF-1-speci®c probe, hybridization to a G3PDH-speci®c probe was used as a loading control Figure 5 H-REV107-1 suppresses colony formation in A27/ 80 cells but not in OVCAR-3 cells. Formation of G418-resistant colonies was measured after transfection of H-REV107-1 into A27/80 and OVCAR-3 cells. The mean values of four independent experiments performed with two dierent plasmid preparations are shown. The colonies/cm 2 obtained after transfection of the EGFP control plasmid were set 100% in each experiment H-REV107-1 is a target of interferon-regulatory factor-1 C Sers et al 100 U/ml IFNg resulted in a parallel up-regulation of H-REV107-1 and IRF-1, a major regulator of IFNresponsive genes that is also involved in oncogenesis as a tumour suppressor (Tanaka and Taniguchi, 2000) . We con®rmed a direct transcriptional control of IRF-1 on the H-REV107-1 target using a conditional IRF-1 expression vector in NIH3T3 cells. H-REV107-1 expression was also induced upon transient transfection of ovarian carcinoma cells with an IRF-1 expression construct. Several lines of evidence have suggested that IRF-1, besides its role in mediating the eects of interferons in anti-viral defence (De Maeyer and De MaeyerGuignard, 1988) , can suppress tumorigenicity. Cellular transformation induced by c-myc or fosB was suppressed by IRF-1 (Tanaka et al, 1994b) . IRF-1-de®cient mouse embryo ®broblast (MEFs), unlike wild-type MEFs, can be transformed in one step by introduction of mutant HRAS (Tanaka et al, 1994a) . Results from IRF-1 7/7 mice suggested that the loss of IRF-1 per se does not lead to tumour formation, however, the IRF-1-de®ciency signi®cantly increases tumour susceptibility. The mechanism responsible for this is currently unknown, yet the search for IRF-1 target genes might shed some light on the responsible processes. An IRF-1 target gene identi®ed earlier is the lysyl oxidase gene (ras recision gene, rrg-1) (Tan et al, 1996) . Lysyl oxidase is a secreted protein responsible for the maturation of the extracellular matrix and is implicated in the phenotypic reversion of HRAS-transformed NIH3T3 cells (Contente, 1990; Hajnal et al., 1993; Oberhuber et al., 1995) . The two IRF-1 targets, lysyl oxidase and H-REV107-1, share several properties with respect to cellular transformation induced by RAS genes. H-rev107-1 is downregulated in HRAS-transformed cells and expression is restored in phenotypic revertants derived from the transformed cells (Hajnal et al., 1994) . In addition, abundant expression of the two genes was also found in the REF52 rat cells which resemble the phenotype of normal human ®broblasts in that they are refractory toward HRAS transformation (Tchernitsa et al, 1999; Serrano et al., 1997) . The Ras-resistance of REF52 cells can be overcome by expression of E1A which results in the down-regulation of H-rev107-1 (Hajnal et al., 1994) . Previous ®ndings indicated that H-REV107-1 overexpression reverts the RAS-dependent transformed phenotype in cell culture and in nude mice. Therefore H-REV107-1 is likely to be one of the critical IRF-1 targets which mediates susceptibility towards transformation in ®broblasts.
In addition, a direct involvement of IRF-1 in the regulation of cell cycle and apoptosis was described (Tamura et al, 1995) . IRF-1 can cooperate with the to mediate DNA-damage induced cell cycle arrest. However, DNA-damage induced apoptosis in Tlymphocytes is dependent on IRF-1 but independent of p53, suggesting alternative target genes responsible for cell death (Tamura et al, 1995) . Recently, a role for the IRF-1 target CAS in the induction of apoptosis in human colon carcinoma cells was suggested (Jiang et al., 2001) . Our observations in the human ovarian carcinoma cells indicate, that H-REV107-1 is an additional IRF-1 target gene which can be involved in apoptosis in certain tumour cell types.
The human IRF-1 gene was mapped to chromosome 5q31.1 and loss of heterozygosity in this region is frequent in leukemias, preleukemic myelodysplastic syndrome (MDS) Green et al., 1999) and gastric cancer (Tamura et al, 1996) . IRF-1 function can be abrogated by mutation (Nozawa et al., 1998) , exon skipping (Harada et al., 1994) and by binding of the protein product to nucleophosmin, a putative nucleosome assembly factor (Kondo et al., 1997) . This latter process does not include any genetic damage to the IRF-1 gene itself. In ovarian carcinoma cell lines, the IRF-1 gene exhibits features of a class II tumour suppressor. Compared to non-tumorigenic human ovarian epithelial cells (HOSE), OVCAR-3, A27/80 and PA1 cells express signi®cantly reduced levels of IRF-1 mRNA. When we assayed the epithelial cell lines with particularly low IRF-1 expression for their response toward IFNg, a strong up-regulation of IRF-1 was achieved.
In A27/80 cells, induction of H-REV107-1 after IFN-g stimulation is relatively weak and peaks shortly after 24 h. A low responsiveness of the established IRF-1 target genes PKR, encoding double stranded RNA-dependent protein kinase, and 2'-5' oligo adenylate synthetase despite full activation of IRF-1 has been reported in HepG2 cells (Tnani and Baynard, 1999) . These observations suggested that in tumour cells, IRF-1-independent mechanisms which may normally contribute to gene regulation are hampered. In addition, a co-operative action of dierent members of the IRF family including IRF-1 was described to be responsible for maximal induction of the Histone H4 promoter (Ronglin et al., 2001) . Transient transfection of IRF-1 into ovarian carcinoma cells induced H-REV107-1, however, expression seemed to decline 24 h post-transfection. In the NIH3T3 cells, harbouring an inducible IRF-1, high levels of H-rev107-1 mRNA could still be detected after 48 h. This dierence can be the result of the very high IRF-1 expression levels in the NIH3T3 cells. In addition, it could be due to tumour-speci®c alterations in IRF-1-dependent gene activation or to the lack of sucient levels of additional IRF family members in ovarian carcinoma cells. When we compared RNA and protein levels, H-REV107-1 protein was hardly detectable in cells after IFNg-induced mRNA induction. This suggests an additional regulatory constraint within tumour cells that prevents accumulation of H-REV107-1 protein levels necessary and sucient for the induction of growth inhibition or cell death. Despite the low levels of induction, H-REV107-1 up-regulation was sucient to contribute to the IFN-g-induced growth inhibition in A27/80 cells.
In OVCAR-3 cells, endogenous H-REV107-1 mRNA levels are higher and the IFNg-mediated induction is more pronounced than in A27/80 cells. However, we have found OVCAR-3 cells refractory to both IFN-g and H-REV107-1-induced growth inhibition. Resistance of OVCAR-3 cells to IFN-g-mediated growth inhibition could involve a negative feed-back loop. Incubation of the cells with 1000 U/ml IFN-g caused a rapid induction of IRF-1 with maximal levels after 3 h. During the following time points, IRF-1 levels decreased constantly (Figure 3a lower panel) . Whether this is due to a concomitant increase of IRF-2 or other negative regulators of IFN-g signalling such as JAB/SOCS-1 (Yasukawa et al, 2000) is currently unknown. Of equal importance is the fact, that only a minority of the cells express high levels of H-REV107-1 protein. This is especially visible after treatment with IFNg when less than 5% of the cells can be stained for H-REV107-1 protein and only these cells show an abnormal nuclear morphology indicative of apoptosis. This may re¯ect a similar low number of cells expressing IRF-1 in response to IFNg. Alternatively, all cells express IRF-1, but only a small fraction of them also induces the target H-REV107-1. Furthermore, the complexity of the interferon-dependent mechanism of growth inhibition involves the expression of other growth suppressors frequently inactivated in ovarian carcinomas. Among them are BRCA1 (Ouchi et al., 2000) and the cyclin dependent kinase inhibitor p21 WAF1/CIP1 (Burke et al., 1999) . In a way similar to SKOV-3 cells, OVCAR-3 cells have also been shown to express high levels of PI3-kinase activity and are sensitive towards growth inhibition by LY294002 (Shayesteh et al., 1999) . The predominance of the PI-3 kinase pathway in these cells might render them resistant to H-REV107-1 induction and interferondependent growth suppression.
The H-REV107-1 gene shares properties as a negative growth modulator with its close relative TIG3/H-REV107-2 (Husmann et al., 1998) which was identi®ed as a retinoic acid-inducible gene (DiSepio et al., 1998) . While H-REV107-1 contributes to IFNg-dependent growth arrest, TIG3/H-REV107-2 acts in a similar way after induction by retinoic acid. Like IFNg, retinoic acid plays an important role in the regulation of dierentiation and cell growth control, respectively (Evans and Kaye, 1999; Rohwedel et al., 1999) . These properties have lead to the application of retinoic acid and IFNg in the therapy of certain leukemias and ovarian cancer (Chelbi-Alix and Pelicano, 1999; Windbichler et al, 2000) . The major eect of IFNg in tumour therapy is attributed to its capacity of enhancing immunogenicity by up-regulation of cell surface antigens. The identi®ca-tion of the growth-inhibitory H-REV107-1 family members as IFNg-and retinoic acid signalling targets, strongly supports a role of these substances in direct proliferation control and tumour chemotherapy. In summary, the transcriptional down-regulation by active RAS signal transduction pathways and the loss of gene induction by IRF-1 is likely to be an important mechanism of class II tumour suppressor dysfunction.
Materials and methods
Tissue samples
Frozen and paran-embedded tissue samples were collected at the Institute of Pathology, University Hospital ChariteÂ , Berlin, Germany. Histopathological diagnosis and grading of the tumours were performed according to established diagnostic criteria. The matched tissue samples used for RT ± PCR analysis included three normal ovaries, one dysgerminoma, one adeno®broma and one tumour of borderline malignancy.
RNA preparation
Tumour samples were homogenized under liquid nitrogen and dissolved in lysis buer from the Atlas pure RNA isolation kit (Clontech, Palo Alto, CA, USA). RNA was prepared according to the protocol supplied by the manufacturer. The RNA was incubated for 30 min at 378C with 2 U of RNAse-free DNAse and re-extracted with phenol once. To control for DNA contamination, a PCR reaction using primers speci®c for Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) was carried out from 50 ng of total RNA.
RT ± PCR
RT ± PCR reactions were carried out in 25 ml using the Titan Kit (Roche, Mannheim, Germany). Fifty ng of total RNA were used per reaction and reverse transcription was performed for 30 min at 508C. Subsequent PCR ampli®cation was performed using the following cycling parameters: 5 min at 948C then 30 cycles of 30 s at 948C, 30 s at 548C, 1 min at 688C and a ®nal extension of 5 min at 688C. Ten ml per reaction were separated via gel electrophoresis. The primers used for the ampli®cation of the 565 bp H-REV107-1-speci®c fragment were: 107-A 5' CTACGCAGCGAAATCGAGCC 3' and 107-G 5' GTCATCGCTGACAGACAGTC 3'. For the ampli®cation of a 771 bp G3PDH-speci®c fragment the G3PDH fw primer 5' GAACGGGAAGCTTGTCATTCA 3' and the G3PDH rv primer 5' GTAGCCAAATTCGTTGT-CATAC 3' were used and ampli®cation was performed for 30 cycles at 568C.
Northern blot and Cancer Profiling Array hybridization
For Northern blot preparation, 10 mg of total RNA were separated by electrophoresis through a 1.2% agarose gel and blotted onto Hybond N nylon membrane (AmershamPharmacia, Buckinghamshire, UK). The following probes were used for hybridization: A 384 bp cDNA fragment derived from the 5' untranslated sequence of human H-REV107-1; a 523 bp cDNA fragment containing the 5' untranslated sequence and a part of the coding sequence of rat Hrev107-1 and a 385 bp fragment ampli®ed from the human IRF-1 sequence using the IRF-1 fw primer 5' CTG GGA CAT CAA CAA GGA TG 3' and IRF-1 rv 5' GTA GCT GCT GTG GTC ATC AG 3'. All probes were 32 P-labelled using nick translation (AmershamPharmacia, Buckinghamshire, UK). Hybridization was carried out for 2 h at 658C using the ExpressHyb Mix (Clontech, Palo Alto, CA, USA) or the Rapid-hyb buer (AmershamPharmacia, Buckinghamshire, UK). Membranes were washed in 0.26SSC/0.1% SDS and exposed to Biomax MS ®lms using intensifying screens (Eastman, Rochester, NY, USA). Stripping of the blots was performed for 20 min in 1% SDS, 0.16SSC, 40 mM Tris/ HCl (pH 7.5) at 1008C prior to hybridization with a 28S-speci®c or a GP3DH-speci®c probe using the conditions described above. The Cancer Pro®ling Array (Clontech, Palo Alto, CA, USA) was hybridized overnight and washed under conditions described above. Quantitative evaluation of the array was performed by phospho-image analysis using a GS250 molecular imager (BioRad, Hercules, CA, USA).
Expression constructs
Human H-REV107-1 expression constructs were used as described (Husmann et al., 1998) . Brie¯y, the cDNA clone 8-1 in pcDNA3 contains the complete open reading frame, 62 bp of 5' untranslated region and 174 bp of 3' untranslated region. pcDNA3 (Invitrogen) and the EGFP plasmid (enhanced green uorescent protein; Clontech) were used as negative controls. The ER-IRF-1 fusion construct was described (Kirchho and Hauser, 1999) . Human IRF-1 expression plasmids were obtained from Invitrogen (Genestorm, Invitrogen, Groningen, Netherlands) or from T Maniatis (Harvard University; Palombella and Maniatis, 1992).
Cell culture and colony formation assays
Human epithelial ovarian carcinoma cell lines SKOV-3, A27/ 80, OVCAR-3, ES-2, the teratocarcinoma cell line PA1, the rat ovarian epithelial cells Rose 199 (Adams and Auersperg, 1985) and a KRAS-transformed derivative Rose A2/5, were maintained in Dulbecco's modi®ed Eagles Medium (DMEM, BioWhittaker, Walkersville, MD, USA) supplemented with 10% fetal calf serum and 2 mM glutamine. Human ovarian surface epithelial cells (HOSE; Tsao et al, 1995) were cultivated in a 1 : 1 mixture of medium 199 (Sigma, Deisenhofen, Germany) and MCDB105 (LifeTechnologies, Karlsruhe, Germany) supplemented with 10% fetal calf serum and 2 mM glutamine. The KA1-10/96-1A cell line (Kirchho and Hauser, 1999) harbouring a fusion construct of estrogen receptor and interferon regulatory factor-1 (ER-IRF-1) was cultivated in DMEM supplemented with 10% low estrogen serum (Roche, Mannheim, Germany). For colony formation assays, 2610 5 cells per well of a 6-well plate were transfected with 1.5 mg plasmid DNA using Fugene (Roche, Mannheim, Germany). Forty-eight hours post transfection, G418 was added at 0.6 mg/ml to the culture medium. Selection was continued for 10 to 14 days until colonies were visible. Colonies were ®xed in methanol, stained in methylen blue and counted.
Western blot
For protein analysis, cells were lysed in TNE buer (10 mM Tris-HCl pH 7.8, 150 mM NaCl, 1 mM EDTA, 1% NP ± 40, protease inhibitor complete TM Roche, Mannheim, Germany). 26sample buer was added to the cell extracts (120 mM TrisHCl, pH 6.8, 200 mM Dithiothretiol, 4% SDS, 20% glycerol, 0.002% bromphenol blue), boiled for 10 min, centrifuged, and aliquots were stored at 7208C. Thirty mg protein were separated on a polyacrylamide gel and blotted onto a PVDF membrane (AmershamPharmacia, Buckinghamshire, UK). Membranes were blocked for 1 h in 5% non-fat dry milk and incubated with the rabbit anti-H-REV107-1 serum produced by immunization with the peptide NKHDDKYSPLPC and diluted 1 : 500 overnight at 48C. Blots were washed with TBST and incubated with a peroxidase-conjugated goat anti-rabbit antiserum diluted 1 : 10 000 (Dianova, Hamburg, Germany) in TBST for 1 h at room temperature. Blots were developed using the ECL system (AmershamPharmacia, Buckinghamshire, UK) and afterwards stripped using the Western blot recycling kit (Alpha Diagnostics, San Antonio, TX, USA). The IRF-1 and IRF-2 antisera (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used at 1 : 1000, the mouse pan-actin antibody (Chemicon, Temecula, CA, USA) was used at 1 : 5000 and developed using a peroxidase-conjugated goat anti-mouse (Dianova, Hamburg, Germany) at 1 : 10 000 in TBST.
Immunofluorescence
Immuno¯uorescence was performed essentially as described (Sers et al., 1997) . The H-REV107-1 antiserum was diluted 1 : 2000 in PBS/1% BSA and coverslips were incubated with a goat anti-rabbit antibody conjugated with Alexa Flour 546 (Molecular Probes, Eugene, OR, USA) at 1 : 300. For nuclear staining, cell were incubated with diamidinophenylindole (DAPI) and analysed using standard¯uorescence or confocal microscopy (Leica).
Immunohistochemistry
Immunohistochemical analysis was conducted on formalin®xed, paran-embedded specimens listed in Table 1 . Two mm sections were deparanized and boiled for 5 min in 10 mM sodium citrate buer, pH 6.0. The rabbit H-REV107-1 antiserum was applied for 1 h diluted 1 : 250. Immunostaining was accomplished using a Dako ChemMate ABC kit (Dako, Hamburg, Germany). The sections were counterstained with hematoxylin and mounted in Permount. Digital images were acquired using an Olympus C3030Z charge-coupled device camera. Adjustments in image contrast were performed identically on the images.
